# Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma

> **NCT03688451** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tahir Latif** · enrollment: 20 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03688451
- **Lead sponsor:** Tahir Latif
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-29
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03688451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03688451, "Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03688451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*